STOCK TITAN
  1. Home
  2. News
  3. BFRG

Bullfrog AI Holdings, Inc. - BFRG STOCK NEWS

Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.

Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) is a dynamic clinical-phase biotechnology company that leverages the power of artificial intelligence and machine learning to advance medical research and improve human health. The company's proprietary platform, bfLEAP™, addresses the challenges of scalability and flexibility in data analysis, offering researchers and clinicians a more precise, multi-dimensional understanding of complex biological data.

Bullfrog AI's core business involves utilizing its AI-driven platform to enhance drug development for both internal projects and collaborations with external partners. The company stands at the forefront of AI-driven drug development, using its technology to create and analyze networks of biological, clinical, and real-world data. This innovation spans from early discovery stages to late-stage clinical trials, aiming to streamline data analytics in therapeutic development, thereby reducing failure rates and development costs.

One of the company's recent significant achievements includes a collaboration with the Lieber Institute for Brain Development (LIBD). This partnership successfully stratified brain expression data from over 2,800 brain samples, offering novel insights into psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Through advanced graph analytics and causal AI, this collaboration identified potential molecular subtypes, biomarkers, and drug targets for these conditions.

Financially, Bullfrog AI recently conducted a public offering of 1,507,139 shares of common stock, priced at $3.782 per share, raising approximately $5.7 million before underwriting discounts and offering expenses. WallachBeth Capital LLC acted as the sole book-running manager for this offering, which is expected to close on February 5, 2024, subject to customary closing conditions.

For more information:

News

WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering

Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. priced an underwritten public offering of 1,507,139 shares of common stock and accompanying warrants, with gross proceeds of approximately $5,700,000. The offering is expected to close on February 5, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
offering AI
-
News

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

Rhea-AI Summary
BullFrog AI Holdings, Inc. announced the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share, resulting in gross proceeds of approximately $5,700,000. The company also granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock and/or warrants to cover over-allotments. The net proceeds from the offering will be used for working capital and other general corporate purposes. The offering is expected to close on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
offering AI
-
News

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

Rhea-AI Summary
BullFrog AI Holdings, Inc. announces the appointment of two distinguished scientific advisors to its advisory board, Dr. Gwenn S. Smith and Dr. Jeremiah Wala. Dr. Smith brings expertise in brain imaging and neuropsychiatry, while Dr. Wala adds clinical insight and computational expertise to the company's scientific advisory board. Both advisors are expected to contribute to the company's mission of developing breakthrough therapies and improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
management AI
News

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

Rhea-AI Summary
BullFrog AI Holdings, Inc. announced early results from its collaboration with the Lieber Institute for Brain Development that could revolutionize the understanding and treatment of psychiatric disorders. The collaboration has successfully stratified brain expression data, offering unprecedented insights into psychiatric conditions. The proprietary data from LIBD included gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. Utilizing graph analytics, BullFrog AI and LIBD have, for the first time, clustered subjects based solely on their biological data, independent of their behavioral diagnoses. This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders. The market opportunity for new treatments in psychiatric disorders is vast and underserved, presenting a potential paradigm shift in treatment approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.83%
Tags
AI
-
News

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This patent further strengthens the intellectual property protection of BF-223 and related compounds, including positive results from a preclinical study demonstrating that BF-223 has anticancer activity in an animal model for glioblastoma. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, addressing a key difficulty associated with the potential use of mebendazole for oncology indications. The company is looking forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
AI
-
News

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announces CEO's participation in Webull LIVE! Healthcare Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences AI
News

BullFrog AI Issues Letter to Shareholders

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has had an extraordinary year, marked by progress, innovation, and value-adding events. The company successfully completed an $8.4 million IPO listing on Nasdaq and secured an exclusive partnership with Lieber Institute for Brain Development. BullFrog AI has also made significant strides in drug development, including identifying drug targets for colorectal cancer and initiating pre-clinical studies for liver disease and obesity drug candidates. The company has strengthened its intellectual property, licensed improvements to its AI algorithms, and recorded its first earned revenue in the third quarter. BullFrog AI's CEO, Vin Singh, is optimistic about the future, emphasizing the company's focus on securing business and driving revenue through external contracts and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
AI
-
News

BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced the launch of a preclinical study led by Dr. Randy Seeley to evaluate the efficacy of its drug candidate BF-114 in treating obesity, NAFLD, and NASH. The study is expected to be completed in Q2 2024 and aims to complement the company’s AI platform for identifying new pathways to target obesity and metabolic diseases. With the market for obesity drugs projected to exceed $77 billion by 2030, the potential impact of BF-114 on these conditions is significant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
clinical trial AI
-
News

ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rhea-AI Summary
RedChip Companies will air interviews with ASP Isotopes Inc. and BullFrog AI Holdings, Inc. on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. ASP Isotopes CEO provides a corporate update, highlighting the completion of the first manufacturing plant and securing multiple supply agreements. BullFrog AI Founder and CEO discusses the company's use of machine learning in drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
AI
News

BullFrog AI to Present at Benzinga All Access Event on October 20

Rhea-AI Summary
BullFrog AI Holdings, Inc. to present at Benzinga's All Access investor event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences AI

FAQ

What is the current stock price of Bullfrog AI Holdings (BFRG)?

The current stock price of Bullfrog AI Holdings (BFRG) is $2.09 as of December 20, 2024.

What is the market cap of Bullfrog AI Holdings (BFRG)?

The market cap of Bullfrog AI Holdings (BFRG) is approximately 18.4M.

What does Bullfrog AI Holdings, Inc. do?

Bullfrog AI Holdings, Inc. is a biotechnology company that uses artificial intelligence and machine learning to advance medical research and drug development.

What is bfLEAP?

bfLEAP is Bullfrog AI's proprietary AI/ML platform that provides a precise, multi-dimensional understanding of complex biological data, aiding in drug development.

What are Bullfrog AI's recent achievements?

One notable achievement is their collaboration with the Lieber Institute for Brain Development, which offered new insights into psychiatric conditions using over 2,800 brain samples.

How does Bullfrog AI's technology benefit drug development?

Bullfrog AI's technology streamlines data analytics, reducing failure rates and overall development costs for new therapeutics.

What financial activities has Bullfrog AI recently conducted?

Bullfrog AI recently conducted a public offering of 1,507,139 shares of common stock, raising approximately $5.7 million.

Who managed Bullfrog AI's recent public offering?

WallachBeth Capital LLC acted as the sole book-running manager for the recent public offering.

How does Bullfrog AI collaborate with other institutions?

Bullfrog AI collaborates with leading research institutions, using its bfLEAP platform to enhance drug development through advanced data analysis.

What is the focus of Bullfrog AI's collaboration with the Lieber Institute for Brain Development?

The focus is on stratifying brain expression data to gain insights into psychiatric conditions and identify potential drug targets.

Where can I find more information about Bullfrog AI?

More information can be found on their website (bullfrogai.com) and LinkedIn page.

Who is the investor contact for Bullfrog AI?

The investor contact is Dave Gentry from RedChip Companies, Inc. You can reach him at BFRG@redchip.com or 800-733-2447.

Stock BFRG logo
Bullfrog AI Holdings, Inc.

Nasdaq:BFRG

BFRG Rankings

#5343 Ranked by Market Cap
N/A Ranked by Dividends

BFRG Stock Data

18.38M
6.17M
29.2%
3.48%
3.28%
Health Information Services
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG